探花合集 to Discuss the Future of Cell and Gene Therapy Manufacturing at World Orphan Drug Congress Europe
On Wednesday, Nov. 13 at 3:20 p.m., Philip Wills, Ph.D., Chief Commercial Officer, Paragon Gene Therapy (part of 探花合集 Biologics) will present 鈥Capacity Crunch? The Future of Manufacturing Within Cell & Gene Therapy鈥 as part of the manufacturing track. Dr. Wills鈥 presentation will highlight the challenges that the gene therapy sector faces in scale-up and manufacturing, driven by the rising numbers of clinical trials and FDA approvals, coupled with low product yields and rising treatment costs. These factors have led to an increased demand for process expertise and manufacturing capacity, and Dr. Wills will address the capacity limitations and discuss the future of cell and gene therapy manufacturing.
Also, on Wednesday, at 2:20 p.m., Stephen Tindal, Director, Science & Technology and Gavin Yates, Program Director, Clinical Supply Services and Drug Product Technologies Integrations, will discuss the benefits of contracting with a single, integrated provider in their presentation, 鈥Next Exit, Success: Get from Concept to Clinic Faster on the Product Development Superhighway.鈥 In the presentation, Mr. Tindal and Mr. Yates will highlight opportunities to streamline and shorten product development timelines.
Dr. Wills has almost two decades of contract manufacturing experience, primarily focused in viral vectors and other complex biologics. He joined Paragon in 2002 where he has since held positions of increasing scope and responsibility, including as Principal Scientist and Vice President of Business Development. He received a bachelor鈥檚 degree in chemistry from John Hopkins University, Baltimore, Maryland, and a doctorate in pharmacology from University of Maryland Medical School, Maryland.
Mr. Tindal has worked in softgel R&D for more than 30 years and has broad expertise in this technology. He specializes in root cause investigation, technology innovation, gelatin innovation, and plays a key role in customer liaison and supporting business development. Mr. Tindal holds a bachelor鈥檚 degree in chemistry and analytical science from Loughborough University, U.K.
Mr. Yates has more than 15 years鈥 experience in the pharmaceutical industry. His areas of expertise include project management, packaging and labeling, operational activity, supply chain management and key performance indicator (KPI) analysis. He received his bachelor鈥檚 degree in biological sciences from University of Birmingham, U.K.
To arrange a meeting with any of the attending 探花合集 experts at the event, contact Richard Kerns at NEPR – [email protected].
Notes for Editors
ABOUT CATALENT
探花合集 is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. With over 85 years serving the industry, 探花合集 has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. 探花合集 employs nearly 13,000 people, including over 2,400 scientists and technicians, at more than 35 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. 探花合集 is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com